Advertisement
Advertisement
February 16, 2016
OCCLUDE Postmarket Study of the ArtVentive EOS Begins in Europe
February 17, 2016—ArtVentive Medical Group, Inc. announced the start of enrollment in the OCCLUDE postmarket surveillance study of the ArtVentive EOS endoluminal occlusion system. The first case was performed at The University Hospital in Leuven, Belgium, where Geert Maleux, MD, successfully treated a patient with the ArtVentive EOS device.
According to the company, the catheter-based, self-expanding EOS device facilitates permanent or temporary occlusion of peripheral body lumens. The device serves as a platform for use in several clinical settings, including peripheral and neurovascular disorders, women's health, interventional cardiology, pulmonary, and interventional oncology procedures.
In the company’s press release, Prof. Maleux commented, “The ArtVentive EOS device enhances our ability to treat challenging embolization cases. It offers immediate and complete occlusion. The operator can have confidence that the target vessel is occluded. The ArtVentive EOS technology allows for shorter procedure times and potentially reduced radiation exposure for both the physician and patient."
Advertisement
Advertisement
